Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, Quebec, Canada.
Am J Physiol Cell Physiol. 2023 Aug 1;325(2):C406-C419. doi: 10.1152/ajpcell.00506.2022. Epub 2023 Feb 6.
The present study tested the hypothesis that protein kinase C-α (PKC-α) recruitment in the presence of the p38α/β MAPK inhibitor SB203580 facilitated the appearance and cell cycle re-entry of nestin-neonatal rat ventricular cardiomyocytes (NNVMs) and induced a transcript profile delineating a proliferative phenotype. Phorbol 12,13-dibutyrate (PDBu) treatment did not induce de novo nestin expression or increase the cell cycle re-entry of 1-day-old NNVMs but significantly increased runt-related transcription factor 1 (Runx1) and p16 cell cycle inhibitor (CDKN2a) mRNA levels and downregulated epithelial cell transforming 2 (ECT2) mRNA expression. SB203580 administration to PDBu-treated NNVMs induced de novo nestin expression, preferentially increased the density (normalized to 500 NNVMs) of nestin-NNVMs that incorporated 5-bromo-2'-deoxyuridine (PDBu, 1.4 ± 3 vs. PDBu/SB203580, 128 ± 34; = 5 independent litters), significantly inhibited CDKN2a and Runx1 mRNA upregulation and reversed ECT2 mRNA downregulation. PDBu treatment of NNVMs reduced PKC-α, protein kinase-δ (PKC-δ) and protein kinase-ε (PKC-ε) protein levels and GF109203X (conventional PKC isoform inhibitor) selectively attenuated PKC-α protein downregulation. GF109203X administration to PDBu/SB203580-treated NNVMs significantly reduced the density of nestin-NNVMs that incorporated 5-bromo-2'-deoxyuridine (PDBu/SB203580/GF109203X, 40 ± 46; = 5). Moreover, GF109203X/PDBu/SB203580 treatment unmasked the predominant appearance of a separate NNVM population that incorporated 5-bromo-2'-deoxyuridine (PDBu/SB203580/GF109203X, 192 ± 42; = 5) delineated by the absence of de novo nestin expression. Sotrastaurin (conventional/novel PKC isoform inhibitor) administration to PDBu/SB203580-treated NNVMs significantly attenuated the density of nestin-NNVMs (PDBu/SB203580/sotrastaurin, 8 ± 10; = 4) and nestin-NNVMs (PDBu/SB203580/sotrastaurin, 64 ± 30; = 4) that incorporated 5-bromo-2'-deoxyuridine. These data reveal that the neonatal rat heart contains at least two separate populations of NNVMs that re-enter the cell cycle and the preferential appearance of nestin- or nestin-NNVMs is driven by distinct PKC isoforms in the presence of SB203580. The appearance of nestin-neonatal rat ventricular cardiomyocytes that re-entered the cell cycle following phorbol ester stimulation in the presence of p38α/β MAPK inhibitor SB203580 was associated with the inhibition of Runx1 and CDKN2a mRNA upregulation. PKC-α selectively induced the cell cycle re-entry of nestin-neonatal rat ventricular cardiomyocytes. Pharmacological inhibition of PKC-α with concomitant p38α/β MAPK suppression unmasked the cell cycle re-entry of a second population of neonatal rat ventricular cardiomyocytes in the absence of nestin expression.
蛋白激酶 C-α(PKC-α)在 p38α/β MAPK 抑制剂 SB203580 的存在下募集,促进巢蛋白-新生大鼠心室肌细胞(NNVMs)的出现和细胞周期再进入,并诱导一种转录谱,描绘出增殖表型。佛波醇 12,13-二丁酸(PDBu)处理不会诱导巢蛋白的从头表达或增加 1 天龄 NNVMs 的细胞周期再进入,但显著增加 runt 相关转录因子 1(Runx1)和 p16 细胞周期抑制剂(CDKN2a)mRNA 水平,并下调上皮细胞转化 2(ECT2)mRNA 表达。SB203580 给药于 PDBu 处理的 NNVMs 诱导巢蛋白的从头表达,优先增加了掺入 5-溴-2'-脱氧尿苷(PDBu,1.4 ± 3 与 PDBu/SB203580,128 ± 34; = 5 个独立的 litter)的巢蛋白-NNVMs 的密度,显著抑制 CDKN2a 和 Runx1 mRNA 的上调,并逆转 ECT2 mRNA 的下调。PDBu 处理 NNVMs 降低了 PKC-α、蛋白激酶-δ(PKC-δ)和蛋白激酶-ε(PKC-ε)蛋白水平,GF109203X(常规 PKC 同工型抑制剂)选择性减弱了 PKC-α 蛋白的下调。GF109203X 给药于 PDBu/SB203580 处理的 NNVMs 显著降低了掺入 5-溴-2'-脱氧尿苷的巢蛋白-NNVMs 的密度(PDBu/SB203580/GF109203X,40 ± 46; = 5)。此外,GF109203X/PDBu/SB203580 处理揭示了 NNVMs 的另一个单独群体的主要出现,该群体掺入 5-溴-2'-脱氧尿苷(PDBu/SB203580/GF109203X,192 ± 42; = 5),没有巢蛋白的从头表达。索他洛尔(常规/新型 PKC 同工型抑制剂)给药于 PDBu/SB203580 处理的 NNVMs 显著减弱了巢蛋白-NNVMs 的密度(PDBu/SB203580/sotrastaurin,8 ± 10; = 4)和掺入 5-溴-2'-脱氧尿苷的巢蛋白-NNVMs(PDBu/SB203580/sotrastaurin,64 ± 30; = 4)。这些数据表明,新生大鼠心脏至少包含两个单独的 NNVM 群体,它们重新进入细胞周期,并且在 SB203580 的存在下,巢蛋白或巢蛋白-NNVMs 的优先出现是由不同的 PKC 同工型驱动的。在 p38α/β MAPK 抑制剂 SB203580 存在下,佛波醇酯刺激后新生大鼠心室肌细胞重新进入细胞周期时出现巢蛋白,与 Runx1 和 CDKN2a mRNA 上调的抑制有关。PKC-α 选择性诱导巢蛋白-新生大鼠心室肌细胞的细胞周期再进入。PKC-α 的药理学抑制与同时抑制 p38α/β MAPK 一起揭示了缺乏巢蛋白表达的新生大鼠心室肌细胞的第二个群体的细胞周期再进入。